Predicting Prognosis in Internal Medicine: A Short and Long-Term Mortality Comparison Analysis

Guerreiro, Renato; Henriques, Célia; Trevas, Sara; Gouveia, Cláudio; Roldão, Marta; Sousa, Inês Egídio de; Faria, C.; Pimenta, Gonçalo; Araújo, Inês; Fonseca, Cândida

doi:10.7759/cureus.21734

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was also a high prevalence of ID (19%) and IDA (40%) among IM patients [ 112 ]. More recently, in a series of 681 patients admitted to an IM ward, anemia on discharge was shown to be a predictor of short-term (6 months) and long-term (1, 3, and 5 years) mortality, independently of the reason for admission [ 113 ]. Therefore, all institutions should implement a protocol for the timely diagnosis and appropriate treatment of anemia in patients admitted to the IM ward.…”

Section: Sucrosomial ® Iron For the Management Of ...mentioning

confidence: 99%

Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency

Gómez‐Ramírez

Brilli²,

Tarantino³

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Iron deficiency (ID) and iron deficiency anemia (IDA) are highly prevalent worldwide. Oral iron salts, especially ferrous sulfate, are commonly used for the treatment of iron deficiency (ID). However, its use is associated with gastrointestinal side effects, thus compromising treatment compliance. Intravenous iron administration is a more costly and logistically complex alternative and is not risk-free, as infusion and hypersensitivity reactions may occur. Sucrosomial® iron is an oral formulation consisting of ferric pyrophosphate conveyed by a phospholipid and sucrester matrix (sucrosome®). Intestinal Sucrosomial® iron absorption is mediated by enterocytes and M cells, through the paracellular and transcellular routes, and occurs mostly as intact particles. These pharmacokinetic properties of Sucrosomial® iron result in higher iron intestinal absorption and excellent gastrointestinal tolerance compared to oral iron salts. The evidence derived from clinical studies supports the use of Sucrosomial® iron as a valid first option for the treatment of ID and IDA, especially for subjects who are intolerant or refractory to conventional iron salts. Newer evidence also demonstrates the effectiveness of Sucrosomial® iron, with a lower cost and fewer side effects, in certain conditions usually treated with IV iron in current clinical practice.

show abstract

Section: Sucrosomial ® Iron For the Management Of ...mentioning

confidence: 99%

Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency

Gómez‐Ramírez

Brilli²,

Tarantino³

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…However, no clear explanation or conclusive evidence for this paradox has been reported so far [8,9]. In recent years, some studies have predicted the long-term mortality of older outpatients and communitydwelling older adults [10][11][12][13]. The Amsterdam Ageing Cohort classi ed the common geriatric syndrome into 5 domains.…”

Section: Introductionmentioning

confidence: 99%

Gender-specific Association of Frailty, Polypharmacy, and the Five-year Mortality Risk: A Real-world Retrospective Study

Lin

Chen

Chou

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: With higher age, frailty escalates the risk of falls, unexpected physical dysfunction, hospitalization, and mortality. Polypharmacy in the older population is a major challenge that not only increases medical costs, but also may worsen the risk of hospitalization and death. This study aimed to investigate the sex difference in the association of polypharmacy and frailty with mortality.Methods: Participants older than 65 years who attended the geriatric outpatient clinic of the study center between January 2015 and July 2020 were invited to participate in this retrospective study. Comprehensive geriatric assessment (CGA) data were collected and the phenotype of frailty was determined by Fried’s criteria. Cox regression and the Kaplan–Meier curve were used to identify risk factors of 5-year survival along with intergroup differences in the risks.Results: Of the 2077 participants, 47.5% were female. The prevalence of frailty and the rate of polypharmacy were 44.7% and 60.6%, respectively. Higher age, male sex, low body mass index, low Mini-Mental State Examination scores, low activities of daily living, frailty status, polypharmacy, and a high Charlson Comorbidity Index score were significant risk factors that were associated with the 5-year all-cause mortality. Male patients with frailty exhibited the highest risks of mortality compared with male patients without frailty and female patients with or without frailty. Polypharmacy was significantly associated with a higher 5-year mortality rate in the frail male group compared with the non-frail male. Conclusions: Polypharmacy synergistically interacted with frailty and intensified the 5-year mortality risk in a gender-specific manner. To mitigate mortality risks, clinicians should prudently identify polypharmacy in the non-frail male older population.

show abstract

Gender-specific linkages: frailty, polypharmacy, anti-cholinergic burden, and 5-year mortality risk—a real-world analysis

Chou,

Lee,

Lin

et al. 2023

PeerJ

View full text Add to dashboard Cite

Background With higher age, frailty escalates the risk of falls, unexpected physical dysfunction, hospitalization, and mortality. Polypharmacy in the older population is a major challenge that not only increases medical costs, but also may worsen the risk of hospitalization and death. More importantly, the properties of anti-cholinergic drugs contribute various negative effects. This study aimed to investigate the sex difference in the association of polypharmacy, anticholinergic burden, and frailty with mortality. Methods Participants older than 65 years who attended the geriatric outpatient clinic of the study center between January 2015 and July 2020 were invited to participate in this retrospective study. Comprehensive geriatric assessment data were collected and the phenotype of frailty was determined by Fried’s criteria. Cox regression and the Kaplan–Meier curve were used to identify risk factors of 5-year survival along with intergroup differences in the risks. Results Of the 2,077 participants, 47.5% were female. The prevalence of frailty and the rate of polypharmacy were 44.7% and 60.6%, respectively. Higher age, male sex, low body mass index, low Mini-Mental State Examination scores, low activities of daily living, frailty status, polypharmacy, and a high Charlson Comorbidity Index score, and greater anticholinergic burden were significant risk factors that were associated with the 5-year all-cause mortality. Male patients with frailty exhibited the highest risks of mortality compared with male patients without frailty and female patients with or without frailty. Polypharmacy was significantly associated with a higher 5-year mortality rate in the frail male group compared with the non-frail male. In frail female group, individuals with a higher anticholinergic burden (as indicated by the Anticholinergic Cognitive Burden Scale) from drug usage exhibited an elevated 5-year mortality rate. Conclusions Polypharmacy and greater anticholinergic burden, synergistically interacted with frailty and intensified the 5-year mortality risk in a gender-specific manner. To mitigate mortality risks, clinicians should prudently identify polypharmacy and anticholinergic burden in the older population.

show abstract

Predicting Prognosis in Internal Medicine: A Short and Long-Term Mortality Comparison Analysis

Cited by 3 publications

References 23 publications

Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency

Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency

Gender-specific Association of Frailty, Polypharmacy, and the Five-year Mortality Risk: A Real-world Retrospective Study

Gender-specific linkages: frailty, polypharmacy, anti-cholinergic burden, and 5-year mortality risk—a real-world analysis

Contact Info

Product

Resources

About